Hederacoside C

• Description:

  Hederacoside C (Kalopanaxsaponin B) is an ingredient that can be obtained mainly from ivy leaves. Hederacoside C mediates inflammation by inhibiting activation of MAPK/NF-κB and its downstream signaling pathway. Hederacoside C has anti-inflammatory and antibacterial activity[1][2][3].

• Product Name Alternative:

  Kalopanaxsaponin B

• UNSPSC:

  12352005

• Hazard Statement:

  H302

• Target:

  Apoptosis; Bacterial; NF-κB; p38 MAPK

• Type:

  Natural Products

• Related Pathways:

  Anti-infection; Apoptosis; MAPK/ERK Pathway; NF-κB

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Hederacoside-C.html

• Concentration:

  10mM

• Purity:

  99.85

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O[C@H]1[C@]([H])(O[C@@H]2[C@@H](O)[C@@H](O)CO[C@]2(O[C@@H]3[C@@](C)(CO)[C@@](CC[C@]4(C)[C@]5([H])CC=C6[C@@]4(C)CC[C@]7(C(O[C@@H]8O[C@H](CO[C@H]9[C@H](O)[C@@H](O)[C@H](O[C@@]%10([H])[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O%10)[C@@H](CO)O9)[C@@H](O)[C@H](O)[C@H]8O)=O)[C@@]6([H])CC(C)(C)CC7)([H])[C@]5(C)CC3)[H])O[C@@H](C)[C@H](O)[C@H]1O

• Molecular Formula:

  C59H96O26

• Molecular Weight:

  1221.38

• Precautions:

  H302

• References & Citations:

  [1]Zha ZX, et al. Hederacoside C ameliorates colitis via restoring impaired intestinal barrier through moderating S100A9/MAPK and neutrophil recruitment inactivation. Acta Pharmacol Sin. 2023 Jan;44 (1) :105-119.|[2]Akhtar M, et al. Hederacoside-C Inhibition of Staphylococcus aureus-Induced Mastitis via TLR2 & TLR4 and Their Downstream Signaling NF-κB and MAPKs Pathways In Vivo and In Vitro. Inflammation. 2020 Apr;43 (2) :579-594.|[3]Xu HC, et al. Hederacoside-C protects against AGEs-induced ECM degradation in mice chondrocytes. Int Immunopharmacol. 2020 Jul;84:106579.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Natural Products

• Clinical Information:

  No Development Reported

• CAS Number:

  [14216-03-6]